These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 37483480)

  • 1. Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean.
    Ahn JK
    J Rheum Dis; 2023 Apr; 30(2):88-98. PubMed ID: 37483480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches to chronic hyperuricemia and gout.
    Grassi D; Pontremoli R; Bocale R; Ferri C; Desideri G
    High Blood Press Cardiovasc Prev; 2014 Dec; 21(4):243-50. PubMed ID: 24696068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.
    Dehlin M; Jacobsson L; Roddy E
    Nat Rev Rheumatol; 2020 Jul; 16(7):380-390. PubMed ID: 32541923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    Ito S; Torii T; Nakajima A; Iijima T; Murano H; Horiuchi H; Yamanaka H; Honda M
    BMC Pediatr; 2020 Oct; 20(1):481. PubMed ID: 33059648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidities in gout and hyperuricemia: causality or epiphenomena?
    Sumpter NA; Saag KG; Reynolds RJ; Merriman TR
    Curr Opin Rheumatol; 2020 Mar; 32(2):126-133. PubMed ID: 31876630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality.
    Chiou A; England BR; Sayles H; Thiele GM; Duryee MJ; Baker JF; Singh N; Cannon GW; Kerr GS; Reimold A; Gaffo A; Mikuls TR
    Arthritis Care Res (Hoboken); 2020 Jul; 72(7):950-958. PubMed ID: 31074584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current state and prospects of gout treatment in Korea.
    Park EH; Choi ST; Song JS
    Korean J Intern Med; 2022 Jul; 37(4):719-731. PubMed ID: 35811361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street.
    Karis E; Crittenden DB; Pillinger MH
    South Med J; 2014 Apr; 107(4):235-41. PubMed ID: 24937517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperuricemia and gout].
    Gröbner W
    Dtsch Med Wochenschr; 2015 Oct; 140(21):1615-26. PubMed ID: 26488103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gout and cardiovascular risk].
    Němec P
    Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Daniel K. Inouye College of Pharmacy Scripts: Perspectives on the Epidemiology of Gout and Hyperuricemia.
    Roman YM
    Hawaii J Med Public Health; 2019 Feb; 78(2):71-76. PubMed ID: 30766768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Kuriyama S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we manage asymptomatic hyperuricemia?
    Chalès G
    Joint Bone Spine; 2019 Jul; 86(4):437-443. PubMed ID: 30316974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
    Eliseev MS; Novikova AM
    Ter Arkh; 2019 May; 91(5):120-128. PubMed ID: 32598686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
    Ruoff G; Edwards NL
    Postgrad Med; 2016 Sep; 128(7):706-15. PubMed ID: 27558643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
    Premachandra KH; Day RO; Roberts DM
    Curr Opin Nephrol Hypertens; 2021 Mar; 30(2):245-251. PubMed ID: 33399392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management and Cure of Gouty Arthritis.
    Keller SF; Mandell BF
    Rheum Dis Clin North Am; 2022 May; 48(2):479-492. PubMed ID: 35400373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.